Skip to content
Palanor is in early release, with our founding customers.Become a founding customer →
PalanorPalanor

Company Dossier · Health Care

Qiagen

QGENNYSEVENLO, NL-LI, NLMid capWebsite ↗
  • Russell 1000

What Qiagen is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.

Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

  • Latest earnings call or results release (August 6, 2026): sentiment 0.20 on a −1 to +1 scale (mixed), confidence 0.70 of 1.Palanor Discourse
  • 337 institutional managers reported a position at June 30, 2026 (−9 on the quarter before).SEC Form 13F
  • H-1B filings certified in Q2 2026: 1 (1 a year earlier).U.S. Department of Labor (OFLC)

Company Posture covers S&P 500 companies.

No bond term sheets or tagged debt on file for Qiagen yet.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

What the company says

Business

Qiagen: earnings call sentiment

Palanor Discourse score per call, −1 to +1

0.20Data to Aug 2026
ImageDataPalanor calculation
Business

Qiagen: earnings call confidence

Palanor Discourse score per call, 0 to 1

0.70Data to Aug 2026
ImageDataPalanor calculation

Hiring and ownership

Business

Qiagen: H-1B filings certified

Labor Condition Applications by quarter received

1.0Data to Jun 2026
ImageDataU.S. Department of Labor, Office of Foreign Labor Certification disclosure data, dol.gov
Business

Qiagen: institutional holders

Managers reporting a position on Form 13F, by quarter

337.0Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

In the news

Headlines that name Qiagen, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.

30 days
2 headlines
0% positive · 0% negative
90 days
2 headlines
0% positive · 0% negative

Peers

Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

CompanyRevenueFree cash flowThrough
Agilent Technologies A$7.4B$1.3BJul 31, 2026
AbbVie Inc. ABBV$64.4B$18.2BJun 30, 2026
Abbott Laboratories ABT$45.1B$7.4BMar 31, 2026
Align Technology ALGN$4.1B$0.6BJun 30, 2026
Alnylam Pharmaceuticals ALNY$3.7B$0.5BDec 31, 2025
Amgen AMGN$38.1B$10.2BJun 30, 2026
Arrowhead Pharmaceuticals ARWR$0.7B−$0.1BJun 30, 2026
Ascendis Pharma ASND———

Identity

SEC CIK
1015820
Wikidata
Q315287

Built from SEC EDGAR filings (public domain), the Guidance and KPI Ledgers, Palanor Discourse, U.S. Department of Labor filings, USPTO, USAspending and Senate lobbying records, and rights-checked news headlines. Updated nightly; this page was built Oct 22, 2026. How the Dossier is built

S&P 500, S&P 100, S&P MidCap 400 and Dow Jones Industrial Average are trademarks of S&P Dow Jones Indices LLC or its affiliates; Nasdaq-100 is a trademark of Nasdaq, Inc.; Russell 1000 is a trademark of FTSE Russell. Membership is shown for identification only. Palanor is not affiliated with or endorsed by the index owners.

Cookies

We only use essential cookies to keep you signed in and remember your theme. No analytics, no tracking, no ads. See the Privacy Policy for the full read.